Kpi Therapeutics

Description

• KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPIs next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPIs valuation, and drive liquidity and funding through the public markets. KPIs experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer.
• 

  Headquarters:401 Terry Avenue North , Seattle, Washington, United States

  More
• 

  Phone Number: +1 206-788-4600

• 

  Website: https://www.kpitherapeutics.com

• 

  Employees:3

• 

  Revenue:$1 - 10M

• 

  Legal Name:Kpi Therapeutics

• Kpi Therapeutics's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More